The FDA has approved zanubrutinib for the treatment of Waldenstrom’s macroglobulinemia

Share This Post

September 2021: For adult patients with Waldenström’s macroglobulinemia, the FDA has approved zanubrutinib (Brukinsa, BeiGene) (WM).

In ASPEN (NCT03053440), zanubrutinib was compared to ibrutinib in patients with MYD88 L265P mutation (MYD88MUT) WM. Cohort 1 (n=201) patients were randomly assigned to receive either zanubrutinib 160 mg twice day or ibrutinib 420 mg once daily until disease progression or intolerable toxicity. Patients in Cohort 2 were given zanubrutinib 160 mg twice daily and were either MYD88 wildtype (MYD88WT) or MYD88 mutation unknown WM (n=26 and 2, respectively).

Response rate, defined as a partial response (PR) or better as judged by an independent review committee using conventional consensus response criteria from the International Workshop on Waldenström’s Macroglobulinemia-6, was the primary efficacy outcome used to support approval. The length of reaction was another efficacy outcome metric (DOR).

The zanubrutinib arms were approved based on a non-comparative evaluation of response and DOR. The zanubrutinib arm had a response rate of 77.5 percent (95 percent confidence interval: 68.1,85.1). The zanubrutinib group had a 94.4 percent event-free DOR at 12 months (95 percent CI: 85.8, 97.9). Response (CR+VGPR+PR) was detected in 50% of the Cohort 2 participants, according to IRC (13 out of 26 response evaluable patients; 95 percent CI: 29.9, 70.1).

Neutrophil count decreased, upper respiratory tract infection, platelet count decreased, rash, haemorrhage, musculoskeletal pain, haemoglobin decreased, bruising, diarrhoea, pneumonia, and cough are the most common adverse reactions, including laboratory abnormalities, reported with zanubrutinib (20 percent).

The recommended dose of zanubrutinib is 160 mg twice a day or 320 mg once a day.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Limkato Korea’s first CAR T Cell therapy
CAR T-Cell therapy

Limkato: Korea’s first CAR T Cell therapy

South Korea is making significant strides in **CAR T cell therapy**, highlighted by the approval of **Limkato**, the first domestically developed CAR T therapy by **Curocell** in 2023. This milestone reduces reliance on foreign treatments and boosts Korea’s position in the global biotech industry. With strong government support and cutting-edge research, Korea is poised to advance CAR T therapies further, expanding applications and improving accessibility for cancer patients.

TIL therapy for melanoma in China
Melanoma

TIL therapy for melanoma in China

Tumor-Infiltrating Lymphocyte (TIL) therapy represents a promising advancement in the treatment of melanoma, particularly in cases where traditional treatments have failed. In China, the adoption of TIL therapy is gaining momentum, offering new hope to patients battling this aggressive form of skin cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟